Coenzyme Q10 in cardiovascular disease

Salvatore Pepe, Silvana Marasco, Steven Joseph Haas, Freya Louise Sheeran, Henry Krum, Franklin Lawrence Rosenfeldt

Research output: Contribution to journalArticleResearchpeer-review

117 Citations (Scopus)

Abstract

In this review we summarise the current state of knowledge of the therapeutic efficacy and mechanisms of action of CoQ(10) in cardiovascular disease. Our conclusions are: 1. There is promising evidence of a beneficial effect of CoQ(10) when given alone or in addition to standard therapies in hypertension and in heart failure, but less extensive evidence in ischemic heart disease. 2. Large scale multi-centre prospective randomised trials are indicated in all these areas but there are difficulties in funding such trials. 3. Presently, due to the notable absence of clinically significant side effects and likely therapeutic benefit, CoQ(10) can be considered a safe adjunct to standard therapies in cardiovascular disease.
Original languageEnglish
Pages (from-to)S154 - S167
Number of pages14
JournalMitochondrion
Volume7
Publication statusPublished - 2007

Cite this